JP2014504869A - サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー - Google Patents

サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー Download PDF

Info

Publication number
JP2014504869A
JP2014504869A JP2013547867A JP2013547867A JP2014504869A JP 2014504869 A JP2014504869 A JP 2014504869A JP 2013547867 A JP2013547867 A JP 2013547867A JP 2013547867 A JP2013547867 A JP 2013547867A JP 2014504869 A JP2014504869 A JP 2014504869A
Authority
JP
Japan
Prior art keywords
alpha
receptor
alpha body
ligand
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013547867A
Other languages
English (en)
Japanese (ja)
Inventor
イニャス ラスタルス
ジョアン デスメット
マリア ヘンドリクス
アニータ ウェーネルト
ヘールト ミアセマン
Original Assignee
コンプリクス エン ヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンプリクス エン ヴェー filed Critical コンプリクス エン ヴェー
Publication of JP2014504869A publication Critical patent/JP2014504869A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013547867A 2011-01-06 2012-01-06 サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー Pending JP2014504869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2011050138 2011-01-06
EPPCT/EP2011/050138 2011-01-06
PCT/EP2012/050193 WO2012093172A1 (en) 2011-01-06 2012-01-06 Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors

Publications (1)

Publication Number Publication Date
JP2014504869A true JP2014504869A (ja) 2014-02-27

Family

ID=44242740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013547867A Pending JP2014504869A (ja) 2011-01-06 2012-01-06 サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー

Country Status (9)

Country Link
US (1) US20140057830A1 (enExample)
JP (1) JP2014504869A (enExample)
CN (1) CN103339148A (enExample)
AU (1) AU2012204846B2 (enExample)
BR (1) BR112013017367A2 (enExample)
CA (1) CA2821646A1 (enExample)
DK (1) DK2661447T3 (enExample)
IN (1) IN2013MN01394A (enExample)
WO (1) WO2012093172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
IN2014MN01562A (enExample) * 2012-01-06 2015-05-08 Complix Nv
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
WO2014064080A1 (en) 2012-10-22 2014-05-01 Complix Nv Polypeptides specifically binding to il-23
EP2909233B1 (en) 2012-10-22 2016-12-07 Complix NV Polypeptides capable of cellular internalization
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2017102835A1 (en) * 2015-12-14 2017-06-22 Complix Nv Binding molecule comprising an alphabody-polypeptide and an antibody
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
CN113315431B (zh) * 2021-04-22 2023-07-28 湖南工业大学 基于等价输入干扰系统的pmsm失磁故障控制方法、电机
CN114544812B (zh) * 2022-02-18 2023-06-30 复旦大学附属中山医院 一种代谢组合式标志物在诊断哮喘中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161278A1 (en) * 2008-09-08 2010-03-10 Complix N.V. Single-chain coiled coil scaffold
WO2010066740A1 (en) * 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
JP2014506131A (ja) * 2011-01-06 2014-03-13 コンプリクス エス アー アルファボディーライブラリーおよびその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161278A1 (en) * 2008-09-08 2010-03-10 Complix N.V. Single-chain coiled coil scaffold
WO2010066740A1 (en) * 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
JP2014506131A (ja) * 2011-01-06 2014-03-13 コンプリクス エス アー アルファボディーライブラリーおよびその製造方法

Also Published As

Publication number Publication date
BR112013017367A2 (pt) 2016-11-22
AU2012204846B2 (en) 2016-09-08
DK2661447T3 (en) 2015-11-02
WO2012093172A1 (en) 2012-07-12
IN2013MN01394A (enExample) 2015-06-12
CA2821646A1 (en) 2012-07-12
AU2012204846A1 (en) 2013-07-04
CN103339148A (zh) 2013-10-02
US20140057830A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
AU2012204846B2 (en) Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
JP7084965B2 (ja) 特異的結合ポリペプチドおよびその使用
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
KR102320189B1 (ko) 특이적 결합 분자의 합성 라이브러리
CN103328507B (zh) Alphabody文库及其产生方法
JP2019501885A (ja) 多特異性抗体
JP2019501887A (ja) 多特異性抗体
JP2019507104A (ja) 二重特異性抗体を用いる方法
Finch et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics
JP2009501517A (ja) Ｉｌ−６結合タンパク質
EP2661447B1 (en) Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
US11248036B2 (en) Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same
US20230391891A1 (en) Il28a receptor binding synthetic cytokines and methods of use
CN102660551B (zh) 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用
CA2418913A1 (en) Peptide mimetics
WO2023205333A2 (en) Tumor necrosis factor receptor 1 antagonist polypeptides and methods of use thereof
CN118620057A (zh) Il-1r1胞外区多肽突变体及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170926